Cogent Biosciences’ (COGT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Cogent Biosciences (NASDAQ:COGT) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $21.00 target price on the technology company’s stock. HC Wainwright also issued estimates for Cogent Biosciences’ Q3 2025 earnings at ($0.64) EPS, Q4 2025 earnings at ($0.59) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($2.05) EPS.

Other analysts also recently issued research reports about the company. Raymond James Financial assumed coverage on Cogent Biosciences in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $30.00 price objective for the company. Robert W. Baird upped their price target on shares of Cogent Biosciences from $7.00 to $9.00 and gave the company a “neutral” rating in a report on Tuesday, July 8th. Citigroup increased their price target on shares of Cogent Biosciences from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, July 18th. Stifel Nicolaus started coverage on shares of Cogent Biosciences in a research report on Wednesday, October 15th. They issued a “hold” rating and a $16.00 price objective on the stock. Finally, Leerink Partners upped their price objective on shares of Cogent Biosciences from $16.00 to $18.00 and gave the company an “outperform” rating in a research note on Monday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Cogent Biosciences Stock Performance

COGT stock opened at $14.72 on Tuesday. The firm has a market cap of $1.68 billion, a P/E ratio of -8.27 and a beta of 0.41. The firm’s fifty day moving average is $14.34 and its 200 day moving average is $10.37. Cogent Biosciences has a 52 week low of $3.72 and a 52 week high of $17.15.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, August 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02. As a group, analysts forecast that Cogent Biosciences will post -2.42 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP lifted its position in Cogent Biosciences by 82.3% during the first quarter. Paradigm Biocapital Advisors LP now owns 8,963,655 shares of the technology company’s stock valued at $53,692,000 after buying an additional 4,046,243 shares during the period. Vestal Point Capital LP bought a new position in shares of Cogent Biosciences in the 1st quarter worth about $17,970,000. Emerald Advisers LLC purchased a new position in Cogent Biosciences during the 2nd quarter valued at about $10,381,000. Woodline Partners LP lifted its position in Cogent Biosciences by 175.2% during the 1st quarter. Woodline Partners LP now owns 1,687,540 shares of the technology company’s stock valued at $10,108,000 after acquiring an additional 1,074,375 shares during the period. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in Cogent Biosciences during the second quarter worth about $6,429,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.